Form 4: Clene Inc. Director David J. Matlin Acquires Stock Options

Director David J. Matlin reports acquisition of stock options in Clene Inc.

Summary

• On May 29, 2024, David J. Matlin, a director of Clene Inc., acquired stock options for 30,000 shares of Common Stock.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan with an exercise price of $0.37 per share.
• The options vest in 12 equal monthly installments starting June 29, 2024, and will be fully vested by May 2025.
• Following the transaction, Matlin beneficially owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard stock option grant to a director, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is fairly typical, encouraging continued service and alignment with shareholder value.
• Comparable companies in the biotech space, such as BioNTech or Moderna, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates